The DEA might reclassify cannabis, removing it from the list of schedule-1 drugs. This would enable the FDA to conduct medical research, and allow insurance companies to assist patients by lowering the overall cost of medical cannabis. This could be achieved through a co-pay system similar to what is used for prescription medications at pharmacies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.